These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 32008443)

  • 21. USA-Morocco deal may extend drug patents to 30 years.
    Ahmad K
    Lancet; 2003 Dec; 362(9399):1904. PubMed ID: 14672079
    [No Abstract]   [Full Text] [Related]  

  • 22. Science and the law. Working through the patent problem.
    Walsh JP; Cohen WM; Arora A
    Science; 2003 Feb; 299(5609):1021. PubMed ID: 12586928
    [No Abstract]   [Full Text] [Related]  

  • 23. Panel rules against Canada on patent terms for pre-TRIPS patents.
    Elliott R
    Can HIV AIDS Policy Law Newsl; 2000; 5(2-3):43, 45. PubMed ID: 11833196
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The new patent regime and disease priorities in India.
    Gupta I; Guin P; Trivedi M
    Glob Public Health; 2013; 8(1):37-54. PubMed ID: 22845021
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inter Partes Review: Patent Killer No More?
    Chen FC; Lee PS
    Trends Biotechnol; 2019 Jul; 37(7):680-683. PubMed ID: 30890272
    [TBL] [Abstract][Full Text] [Related]  

  • 26. TRIPS: whose interests are being served?
    Kamal M; Bailey M
    Lancet; 2003 Jul; 362(9380):260. PubMed ID: 12892952
    [No Abstract]   [Full Text] [Related]  

  • 27. Plausibility in patent law: an unsettled concept.
    Crawford C; Reynolds L
    Pharm Pat Anal; 2016 Sep; 5(5):289-93. PubMed ID: 27573248
    [No Abstract]   [Full Text] [Related]  

  • 28. A consideration of the patentability of enantiomers in the pharmaceutical industry in the United States.
    Miller CP; Ullrich JW
    Chirality; 2008 Jun; 20(6):762-70. PubMed ID: 18200591
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Intellectual property. Decision on NFkappaB patent could have broad implications for biotech.
    Garber K
    Science; 2006 May; 312(5775):827. PubMed ID: 16690824
    [No Abstract]   [Full Text] [Related]  

  • 30. Will the Modi government succumb to US and industry pressure to modify its pro-access pharmaceutical patent policy?
    Baker BK
    Expert Opin Ther Pat; 2015 Jun; 25(6):625-8. PubMed ID: 25704359
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Myriad diagnostic concerns.
    Nat Biotechnol; 2013 Jul; 31(7):571. PubMed ID: 23839123
    [No Abstract]   [Full Text] [Related]  

  • 32. Intellectual property. Balancing innovation and access: patent challenges tip the scales.
    Higgins MJ; Graham SJ
    Science; 2009 Oct; 326(5951):370-1. PubMed ID: 19833944
    [No Abstract]   [Full Text] [Related]  

  • 33. Intellectual property. U.S. patent reform begins long journey through Congress.
    Kintisch E
    Science; 2005 Jun; 308(5729):1725-6. PubMed ID: 15961638
    [No Abstract]   [Full Text] [Related]  

  • 34. Health-care patents and interests of patients.
    Luthra R
    Bull World Health Organ; 2006 Nov; 84(11):919. PubMed ID: 17143470
    [No Abstract]   [Full Text] [Related]  

  • 35. Intellectual property. Challenges to India's pharmaceutical patent laws.
    Sampat BN; Shadlen KC; Amin TM
    Science; 2012 Jul; 337(6093):414-5. PubMed ID: 22767892
    [No Abstract]   [Full Text] [Related]  

  • 36. Staving off death: a case study of the pharmaceutical industry's strategies to protect blockbuster franchises.
    Gorlin DI
    Food Drug Law J; 2008; 63(4):823-64. PubMed ID: 19601385
    [No Abstract]   [Full Text] [Related]  

  • 37. Favourable changes to the IP and tax systems in the UK for drug development.
    Watson R
    Expert Opin Ther Pat; 2013 Jul; 23(7):773-5. PubMed ID: 23713616
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Managing severe acute respiratory syndrome (SARS) intellectual property rights: the possible role of patent pooling.
    Simon JH; Claassen E; Correa CE; Osterhaus AD
    Bull World Health Organ; 2005 Sep; 83(9):707-10. PubMed ID: 16211163
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Patent necessity: intellectual property dilemmas in the biotech domain and treatment equity for developing countries.
    Spectar JM
    Houst J Int Law; 2002; 24(2):227-78. PubMed ID: 16189914
    [No Abstract]   [Full Text] [Related]  

  • 40. [Evolution of the international intellectual property rights system: patent protection for the pharmaceutical industry and access to medicines].
    Chaves GC; Oliveira MA; Hasenclever L; de Melo LM
    Cad Saude Publica; 2007 Feb; 23(2):257-67. PubMed ID: 17221075
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.